FDA changed the source of facility data it uses to calculate some generic drug user fees in recognition of new fee parameters, but will continue the self-identification process that had been the primary database.
In its announcement of the fiscal year 2018 generic drug user fees, the agency said it calculated the fees for active pharmaceutical ingredient and finished dosage form facilities using application...